Finally, we can put all the upfront work in motion and support value-based program execution. Leveraging the outcomes-based contracting enablement platform and the scale of Optum allows us to measure meaningful outcomes for manufacturers in a consistent and objective way.
How do we bring this home? How do we, collectively, payers, life sciences manufacturers and Optum, do this well?
We’d love to talk to others, just to share ideas, or to find ways to partner with manufacturers and payers in this space. The promise that gene and cell therapies hold for patients is real, and we are excited to work together to ensure that patients have affordable access to these transformative therapies.
Optum is committed to providing solutions that get the right treatments to the right patients at the right time — to meaningfully and measurably improve clinical outcomes and quality of life for patients.
Together, we can reshape health care for the good of all as we continue to innovate and connect disparate parts of the health system.
Thank you, Erin, for the discussion today.
Are you a life sciences manufacturer working on developing, implementing and executing outcomes-based programs?
The Optum value-based services team can leverage the outcomes-based contracting enablement platform to help you get to a standardized infrastructure, data process, and measurement and reporting services that enable outcomes-based contracts with a broad set of payers.